<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00613093</url>
  </required_header>
  <id_info>
    <org_study_id>4260</org_study_id>
    <nct_id>NCT00613093</nct_id>
  </id_info>
  <brief_title>Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma</brief_title>
  <official_title>Phase II Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Temodar-Resistant Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Keryx / AOI Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:&#xD;
&#xD;
      To define role of O6-Benzylguanine (BG) in restoring Temodar (temozolomide) sensitivity in&#xD;
      patients with Temodar-resistant malignant glioma.&#xD;
&#xD;
      To further define toxicity of combo therapy using Temodar + BG.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2 separate strata accrued independently of each other: Stratum 1-patients with Glioblastoma&#xD;
      Multiforme (GBM). Stratum 2-patients with Anaplastic Glioma [anaplastic astrocytoma (AA),&#xD;
      anaplastic oligodendroglioma (AO), anaplastic mixed (AA and AO)] .&#xD;
&#xD;
      BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour&#xD;
      infusion at 30mg/m2/24hrs. Temozolomide 472mg/m2 administered orally, in fasting state,&#xD;
      within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be&#xD;
      repeated every 28 days following dose of Temodar from previous cycle.&#xD;
&#xD;
      Temodar has been well tolerated by both adults and children with most common toxicity being&#xD;
      mild myelosuppression. Other, less likely, potential toxicities include nausea and vomiting,&#xD;
      constipation, headache, alopecia, rash, burning sensation of skin, esophagitis, pain,&#xD;
      diarrhea, lethargy, hepatotoxicity, anorexia, fatigue and hyperglycemia. Hypersensitivity&#xD;
      reactions have not yet been noted with Temodar. As in the case with many anti-cancer drugs,&#xD;
      Temodar may be carcinogenic. BG toxicities include agitation, lethargy, nausea, vomiting,&#xD;
      rapid heart rate, elevated liver functions, &amp; leukemia; but, not with BG as single agent.&#xD;
      Transient lymphopenia has been seen with BG as single agent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic evidence of tumor response</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 month progression-free survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between tumor AGT at original diagnosis &amp; response to Temozolomide + O6-BG</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Anaplastic Glioma</condition>
  <arm_group>
    <arm_group_label>Patients with glioblastoma multiforme</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Anaplastic Glioma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temodar and O6-Benzylguanine (BG)</intervention_name>
    <description>Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).&#xD;
BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle.</description>
    <arm_group_label>Patients with Anaplastic Glioma</arm_group_label>
    <arm_group_label>Patients with glioblastoma multiforme</arm_group_label>
    <other_name>Temodar - Temozolomide</other_name>
    <other_name>O6-Benzylguanine - O6-BG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients have recurrent/progressive Malignant Glioma (MG). Stereotactic biopsy at time&#xD;
             of recurrence/progression is only required if radiation-induced necrosis is suspected&#xD;
&#xD;
          -  Patients have MG resistant to Temodar, which is defined as &gt; or = to 25 percent&#xD;
             increase in tumor growth on contrast enhanced MRI/CT within 8 weeks of last dose of&#xD;
             Temodar&#xD;
&#xD;
          -  Age &gt; or = to 18 years&#xD;
&#xD;
          -  Evidence of measurable enhancing disease on contrast-enhanced MRI, unless medically&#xD;
             contraindicated.&#xD;
&#xD;
          -  Interval of at least 2 weeks between prior surgical resection/ 4 weeks between prior&#xD;
             radiotherapy/chemotherapy, and enrollment on protocol unless there is unequivocal&#xD;
             evidence of tumor progression. However, patients treated with chemotherapy agents such&#xD;
             as VP-16 who would normally be retreated after shorter intervals may be treated at&#xD;
             usual starting time even if less than 4 weeks from last prior dose of chemotherapy&#xD;
&#xD;
          -  Karnofsky performance score &gt; or = to 60 percent&#xD;
&#xD;
          -  Hematocrit &gt; 29 percent, absolute neutrophil count (ANC) &gt; 1,500 cells/microliter,&#xD;
             platelets &gt; 100,000 cells/microliter&#xD;
&#xD;
          -  Serum creatinine &lt;1.5 mg/dl, Blood Urea Nitrogen (BUN) &lt;25 mg/dl, Serum Glutamic&#xD;
             Oxaloacetic Transaminase (SGOT) &amp; bilirubin &lt;1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  For patients on corticosteroids, they must have been on stable dose for 1 week prior&#xD;
             to entry, if clinically possible, and dose should not be escalated over entry dose&#xD;
             level&#xD;
&#xD;
          -  Signed informed consent approved by Institutional Review Board (IRB) prior to patient&#xD;
             entry&#xD;
&#xD;
          -  If sexually active, patients will take contraceptive measures for duration of&#xD;
             treatments&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Co-medication that may interfere with study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A. Reardon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cancer.duke.edu/btc/</url>
    <description>The Preston Robert Tisch Brain Tumor Center at DUKE</description>
  </link>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>January 29, 2008</study_first_submitted>
  <study_first_submitted_qc>February 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2008</study_first_posted>
  <last_update_submitted>July 8, 2014</last_update_submitted>
  <last_update_submitted_qc>July 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Temodar</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>O6-BG</keyword>
  <keyword>O6-Benzylguanine</keyword>
  <keyword>NSC 637037</keyword>
  <keyword>Temodar-Resistant Malignant Glioma</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>CNS tumor</keyword>
  <keyword>Cerebral glioblastoma</keyword>
  <keyword>Anaplastic astrocytomas</keyword>
  <keyword>Glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>O(6)-benzylguanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

